The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective
AP Venook, C Papandreou, J Furuse… - The …, 2010 - academic.oup.com
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, and
the burden of this devastating cancer is expected to increase further in coming years. The …
the burden of this devastating cancer is expected to increase further in coming years. The …
Clinical practice guidelines for the management of biliary tract cancers 2015: the 2nd English edition
…, T Tsuyuguchi, N Fujita, J Furuse… - Journal of Hepato …, 2015 - Wiley Online Library
Background The Japanese Society of Hepato‐Biliary‐Pancreatic Surgery launched the clinical
practice guidelines for the management of biliary tract and ampullary carcinomas in 2008…
practice guidelines for the management of biliary tract and ampullary carcinomas in 2008…
Chemotherapy for hepatocellular carcinoma: current status and future perspectives
…, M Ueno, T Okusaka, H Ishii, J Furuse - Japanese journal of …, 2018 - academic.oup.com
Chemotherapy is one of the most important treatment modalities for advanced
hepatocellular carcinoma (HCC). On the basis of the results of two pivotal Phase III placebo-controlled …
hepatocellular carcinoma (HCC). On the basis of the results of two pivotal Phase III placebo-controlled …
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
…, W Sieghart, E Assenat, R Zaucha, J Furuse… - The Lancet …, 2022 - thelancet.com
Background Single-agent nivolumab showed durable responses, manageable safety, and
promising survival in patients with advanced hepatocellular carcinoma in the phase 1–2 …
promising survival in patients with advanced hepatocellular carcinoma in the phase 1–2 …
Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
…, G Lau, M Kudo, SL Chan, RK Kelley, J Furuse… - NEJM …, 2022 - evidence.nejm.org
Background A single, high priming dose of tremelimumab (anti-cytotoxic T lymphocyte–associated
antigen 4) plus durvalumab (anti–programmed cell death ligand-1), an infusion …
antigen 4) plus durvalumab (anti–programmed cell death ligand-1), an infusion …
[HTML][HTML] Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
…, TB Karasic, TA Abrams, J Furuse… - … England Journal of …, 2023 - Mass Medical Soc
Background Alterations in fibroblast growth factor receptor 2 (FGFR2) have emerged as
promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor prognosis. …
promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor prognosis. …
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label …
…, I Hyodo, K Yoshida, H Baba, T Esaki, J Furuse… - The Lancet, 2018 - thelancet.com
Background Patients with advanced gastric or gastro-oesophageal junction cancer that
progresses on chemotherapy have poor outcomes. We compared pembrolizumab with paclitaxel …
progresses on chemotherapy have poor outcomes. We compared pembrolizumab with paclitaxel …
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer …
RK Kelley, M Ueno, C Yoo, RS Finn, J Furuse, Z Ren… - The Lancet, 2023 - thelancet.com
Background Biliary tract cancers, which arise from the intrahepatic or extrahepatic bile ducts
and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide. …
and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide. …
[PDF][PDF] Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in …
…, K Mizumoto, JS Chen, J Furuse… - Journal of Clinical …, 2013 - researchgate.net
… Okusaka T, Funakoshi A, Furuse J, et al: A late phase II study of S-1 for metastatic pancreatic
cancer. Cancer Chemother Pharmacol 61:615-621, 2008 10. Nakamura K, Yamaguchi T …
cancer. Cancer Chemother Pharmacol 61:615-621, 2008 10. Nakamura K, Yamaguchi T …
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial
…, M Peck-Radosavljevic, A Santoro, B Daniele, J Furuse… - Jama, 2014 - jamanetwork.com
Importance Aside from the multikinase inhibitor sorafenib, there are no effective systemic
therapies for the treatment of advanced hepatocellular carcinoma. Objective To assess the …
therapies for the treatment of advanced hepatocellular carcinoma. Objective To assess the …